1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD38

CD38

CD38 is a glycoprotein found on the surface of many immune cells, including T cells, B cells and natural killer cells. Additionally, CD38 has been shown to be a bifunctional enzyme expressing both ADP-ribosyl cyclase and cADPR hydrolase activities. The role of CD38 in immune cells ranges from modulating cell differentiation to effector functions during inflammation, where CD38 may regulate cell recruitment, cytokine release, and NAD availability. In line with a role in inflammation, CD38 appears to also play a critical role in inflammatory processes during autoimmunity. Because of CD38 expression is highly upregulated on human plasma cells and especially on multiple myeloma cells.Targeting of CD38 is one of the most important and promising treatment avenues to help patients suffering from multiple myeloma.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991183
    SAR-442257
    Inhibitor ≥99.0%
    SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells.
    SAR-442257
  • HY-P991715
    Sanritatug
    Inhibitor
    Sanritatug is an anti-CD38 IgG1κ antibody, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001).
    Sanritatug
  • HY-144988
    CD38 inhibitor 2
    98.81%
    CD38 inhibitor 2 is a potent CD38 inhibitor (IC50 = 0.01 ~ 0.1 μΜ).
    CD38 inhibitor 2
  • HY-134358
    Ara-F-NAD+
    Inhibitor
    Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor.
    Ara-F-NAD+
  • HY-181543
    CVN14
    Inhibitor
    CVN14 is a potent, selective and brain-penetrant CD38 inhibitor with human IC50 19 nM, mouse IC50 2.4 nM. CVN14 binds uncompetitively to form a complex with CD38 and ADPR, and inhibits CD38 enzymatic activity. CVN14 can be used for the research of neurodegenerative diseases.
    CVN14
  • HY-P10563
    Noraramtide
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity.
    Noraramtide
  • HY-P992455
    SAR442085
    Inhibitor
    SAR442085 is an Fc-engineered anti-CD38 monoclonal antibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma.
    SAR442085
  • HY-171417
    6-Alkyne-F-araNAD
    Inhibitor
    6-Alkyne-F-araNAD is an irreversible inhibitor of CD38. 6-Alkyne-F-araNAD helps other fluorescent probes (such as SR101−F-araNMN) to more clearly observe the localization of intracellular CD38.
    6-Alkyne-F-araNAD
  • HY-P991913
    CID-103
    Inhibitor
    CID-103 (TSK011010) is an anti-CD38 antibody that recognizes a unique epitope on CD38. CID-103 can be used in research on immune thrombocytopenia.
    CID-103
  • HY-P991461
    AMG-424
    Inhibitor 99.32%
    AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3.
    AMG-424
  • HY-164628
    CD38-IN-5
    Inhibitor
    CD38-IN-5 (compound 1) is a CD38 inhibitor that selectively inhibits CD38 hydrolase with an IC50 of 4.0 μM. CD38-IN-5 does not inhibits CD38 cyclase. CD38-IN-5 is highly effective at promoting NK cell-mediated tumor toxicity. CD38-IN-5 increases NADH+ and IFNγ levels in activated PBMCs. CD38-IN-5 can be used for the study of cancer.
    CD38-IN-5
  • HY-119648A
    (E/Z)-CCR-11
    Inhibitor 98.00%
    (E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ.
    (E/Z)-CCR-11
  • HY-P991462
    GBR-1342
    Inhibitor
    GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research.
    GBR-1342
  • HY-N0640R
    Kuromanin chloride (Standard)
    Inhibitor
    Kuromanin (chloride) (Standard) is the analytical standard of Kuromanin (chloride). This product is intended for research and analytical applications. Kuromanin chloride (Chrysontemin) is derived from mulberry leaves and has the effect of increasing blood sugar concentration and maintaining lipid metabolism balance to reduce obesity. Kuromanin chloride can inhibit CD38 enzymatic activities.
    Kuromanin chloride (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity